Greenwich LifeSciences (GLSI) Share-based Compensation (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Share-based Compensation of $2.2 million for Q4 2025, up 40.57% on a QoQ basis from $1.5 million in Q3 2025, and down 60.31% year-over-year from $5.5 million in Q4 2024.
Greenwich LifeSciences (GLSI) Share-based Compensation (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Share-based Compensation history runs 7 years deep, the most recent figure standing at $2.2 million for Q4 2025.
- Quarterly Share-based Compensation fell 60.31% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.8 million (down 6.2% YoY) and the FY2025 annual result came in at $6.8 million, down 6.2% from the prior year.
- Share-based Compensation was $2.2 million for Q4 2025 at Greenwich LifeSciences, up from $1.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.5 million in Q4 2024 and bottomed at $165051.0 in Q1 2021.
- A 5-year average of $941959.4 and a median of $594522.0 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 820.03% — and 2025, when it slumped 60.31%.
- Greenwich LifeSciences' Share-based Compensation stood at $165429.0 in 2021, then jumped by 259.38% to $594522.0 in 2022, then changed by 0.0% to $594522.0 in 2023, then jumped by 820.03% to $5.5 million in 2024, then tumbled by 60.31% to $2.2 million in 2025.
- Business Quant data shows GLSI's Share-based Compensation at $2.2 million in Q4 2025, $1.5 million in Q3 2025, and $1.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | 2.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.17 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Sep 30, 2025 | 1.54 Mn |
| Sep 30, 2025 | 1.54 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | 1.54 Mn |
| Mar 31, 2025 | 1.54 Mn |
| Dec 31, 2024 | 5.47 Mn |
| Dec 31, 2024 | 5.47 Mn |
| Sep 30, 2024 | 594,522.00 |
| Sep 30, 2024 | 594,522.00 |
| Jun 30, 2024 | 594,522.00 |
| Jun 30, 2024 | 594,522.00 |
| Mar 31, 2024 | 594,522.00 |
| Mar 31, 2024 | 594,522.00 |
| Dec 31, 2023 | 594,522.00 |
| Dec 31, 2023 | 594,522.00 |
| Sep 30, 2023 | 594,522.00 |
| Sep 30, 2023 | 594,522.00 |